Published in Sci Rep on September 22, 2016
Detecting similar binding pockets to enable systems polypharmacology. PLoS Comput Biol (2017) 0.75
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer (2014) 40.30
The many roles of computation in drug discovery. Science (2004) 5.66
Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol (2011) 5.65
The ChEMBL bioactivity database: an update. Nucleic Acids Res (2013) 5.41
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res (2000) 3.95
EGF receptor. Int J Biochem Cell Biol (1999) 3.91
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol (2011) 3.72
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res (2001) 3.55
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res (2004) 2.43
The role of the EGFR signaling in tumor microenvironment. J Cell Physiol (2008) 2.34
Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comput Biol (2010) 1.97
AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res (2004) 1.82
Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol (2011) 1.76
Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today (2005) 1.55
Analysis of drug-induced effect patterns to link structure and side effects of medicines. Nat Chem Biol (2005) 1.33
The SIDER database of drugs and side effects. Nucleic Acids Res (2015) 1.30
Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer (2005) 1.12
Studies with ZD1839 in preclinical models. Semin Oncol (2003) 0.99
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC). Drug Des Devel Ther (2010) 0.92
DSigDB: drug signatures database for gene set analysis. Bioinformatics (2015) 0.90
PockDrug-Server: a new web server for predicting pocket druggability on holo and apo proteins. Nucleic Acids Res (2015) 0.85
sc-PDB: a 3D-database of ligandable binding sites--10 years on. Nucleic Acids Res (2014) 0.85
Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib. Lung Cancer (2008) 0.83
Differential transcriptional effects of EGFR inhibitors. PLoS One (2014) 0.83
Detection of Binding Site Molecular Interaction Field Similarities. J Chem Inf Model (2015) 0.82
Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease. Jpn J Clin Oncol (2013) 0.82
Gefitinib. Profiles Drug Subst Excip Relat Methodol (2014) 0.82
Identification of Similar Binding Sites to Detect Distant Polypharmacology. Mol Inform (2013) 0.80
Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress. Toxicol Lett (2016) 0.77